Get informed when a big investor buys or sells
+ FollowOvervalued by 137.6% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $66.92 Million |
|---|---|
| Enterprise Value | $79.10 Million |
| Earnings per Share | $-0.03 |
| Beta | 2.14 |
| Outstanding Shares | 154,364,273 |
| P/E Ratio | -9.51 |
|---|---|
| PEG | -0.92 |
| Price to Sales | - |
| Price to Book Ratio | -0.43 |
| Enterprise Value to Revenue | 10.72 |
| Enterprise Value to EBIT | -6.9 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -55.12 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their f...